Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medeze Group PCLBKK:MEDEZE -1.59%19 PB Ratio is 2.25 as of Sep. 16, 2026, which is 6% below its 10-year median of 2.39. GuruFocus rates BKK:MEDEZE with a GF Score™ of 19/100. The stock has 5 warning signs investors should review. Among 614 Healthcare Providers & Services companies, Medeze Group PCL ranks worse than 56.84% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-09-16), Medeze Group PCL's share price is ฿6.20. Medeze Group PCL's Book Value per Share for the quarter that ended in Jun. 2026 was ฿2.76. Hence, Medeze Group PCL's PB Ratio of today is 2.25.
Good Sign:
Medeze Group PCL stock PB Ratio (=2.32) is close to 2-year low of 2.17.
The historical rank and industry rank for Medeze Group PCL's PB Ratio or its related term are showing as below:
BKK:MEDEZE'
s PB Ratio Range Over the Past 10 Years
Min: 2.17 Med: 2.39 Max: 3.73
Current: 2.24
During the past 3 years, Medeze Group PCL's highest PB Ratio was 3.73. The lowest was 2.17. And the median was 2.39.
BKK:MEDEZE's PB Ratio is ranked worse than 56.84% of 614
companies
in the Healthcare Providers & Services industry
Industry Median: 1.875
vs BKK:MEDEZE: 2.24
During the past 12 months, Medeze Group PCL's average Book Value Per Share Growth Rate was -0.60% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Medeze Group PCL PB Ratio Related Terms
Medeze Group PCL PB Ratio Historical Data
* Premium members only.
The historical data trend for Medeze Group PCL's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Medeze Group PCL's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medeze Group PCL PB Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Medeze Group PCL's PB Ratio distribution charts can be found below:
* The bar in red indicates where Medeze Group PCL's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Medeze Group PCL (BKK:MEDEZE) has a PB Ratio of 2.25 as of Sep. 16, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Medeze Group PCL and its competitors. This is near median its historical median of 2.39. Over the past decade, Medeze Group PCL's PB Ratio has ranged from 2.17 to 3.73. According to the industry distribution chart, Medeze Group PCL ranks #349 out of 614 companies in the Healthcare Providers & Services industry, placing it in the top 56.8%.
Is Medeze Group PCL's PB Ratio too high?
Medeze Group PCL's current PB Ratio of 2.25 is near median its 10-year median of 2.39. Over the past 10 years, this metric has ranged from a low of 2.17 to a high of 3.73. The Healthcare Providers & Services industry median PB Ratio is 1.88. Medeze Group PCL's value of 2.25 is 20% above this industry median. Based on the distribution chart, Medeze Group PCL ranks #349 out of 614 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Medeze Group PCL has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Medeze Group PCL's PB Ratio compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Medeze Group PCL ranks #349 out of 614 companies for PB Ratio. This places Medeze Group PCL in the lower half of its industry. The industry median PB Ratio is 1.88. Medeze Group PCL's value of 2.25 is 20% above this benchmark. Historically, Medeze Group PCL's own PB Ratio has ranged from 2.17 to 3.73 over the past decade. While the company's 10-year median is 2.39 vs. the industry median of 1.88, Medeze Group PCL has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Healthcare Providers & Services company?
The median PB Ratio among Healthcare Providers & Services companies is 1.88, based on 614 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medeze Group PCL's current PB Ratio of 2.25 is 20% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Medeze Group PCL and its competitors. For the Healthcare Providers & Services industry, the median PB Ratio is 1.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medeze Group PCL's current PB Ratio is 2.25, which is near median its own 10-year median of 2.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medeze Group PCL stock overvalued right now?
Medeze Group PCL (BKK:MEDEZE) has a current PB Ratio of 2.25. The current PB Ratio is 2.25, which is near median its 10-year median of 2.39 and 20% above the Healthcare Providers & Services industry median of 1.88. Medeze Group PCL's overall GF Score™ is 19/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Medeze Group PCL (BKK:MEDEZE), the current PB Ratio is 2.25 as of Sep. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Medeze Group PCL is engaged in the business of providing stem cell storage, analyzing, isolation, cultivation and preservation services for medical use. It is organised into four reportable segments: Stem cell sample collection service segment; White blood cell potential testing service segment; Other services segment and Sales of products segment. Geographically, the company operates in Thailand, Vietnam, Cambodia, Philippines, and Other countries, of which maximum revenue is derived from Thailand.
19GF Score
Get the complete analysis for BKK:MEDEZE
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:MEDEZE has been successfully added to your 
